Cover Story
For more than four decades, Steven Rosenberg's work on tumor infiltrating lymphocytes has met with equal measures of skepticism and cheer—but now, as more patients across multiple cancer types respond to cell transfer immunotherapy, researchers are eager to join the movement Rosenberg indisputably leads.
By Jordan Williams
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Leading a Comprehensive Cancer Center—one job or two?
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- “This is our time, and the time is now”—Chapman tells us about Jefferson’s final push for Comprehensive designation
- Call to action: To address Black cancer disparities, focus on research prioritization and clinical studies inclusion
Minority Cancer Awareness Week - Gynecology’s deadly surprise:
Cancers are frequently missed prior to routine procedures